Metastatic renal cell carcinoma (mRCC) has seen increased treatment options in recent years, including immunotherapy (IO) combinations paired with tyrosine kinase inhibitors (TKI). A meta-analysis of ...

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression ...

During the dark days of December, in many schools throughout the Main Line, students will be heard exclaiming the celebratory “IO SATURNALIA!,” a clarion call throughout the centuries of the Roman ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window It's my pleasure ...

NEW YORK, Sept. 14, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines, ...

Oral-B initially launched the iO line in 2020 to help users achieve superior at-home cleaning. Oral-B iO brushes achieve this through 3D brushing recognition, pressure control, and a built-in brushing ...

Comparing the effectiveness of IO-based combination regimens as first-line treatment for advanced clear-cell renal cell carcinoma (ccRCC). This is an ASCO Meeting Abstract from the 2025 ASCO ...

Is intraosseous vascular access associated with poorer patient outcomes than intravenous access after out-of-hospital cardiac arrest? In a secondary analysis, published in Annals of Emergency Medicine ...

The review of 5 phase 3 randomized controlled trials found that overall, the combination treatments improved survival outcomes while eliciting more, but manageable, side effects. As various ...

The flash memory maker introduces a line of high-capacity products. Fusion-io (FIO.DL) has unveiled a new product line. Dubbed Fusion ioScale by the flash memory maker, the products provide up to 3.2 ...